Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

4.69

Margin Of Safety %

97

Put/Call OI Ratio

1.05

EPS Next Q Diff

-0.1

EPS Last/This Y

0.49

EPS This/Next Y

0.19

Price

6.7

Target Price

10.83

Analyst Recom

3.57

Performance Q

-20.12

Relative Volume

1.26

Beta

0.55

Ticker: OGN




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-10-06OGN10.850.770.4779129
2025-10-07OGN10.60.771.0379764
2025-10-08OGN10.240.770.1179804
2025-10-09OGN9.910.751.2280860
2025-10-10OGN9.60.760.1181764
2025-10-13OGN9.60.760.2281853
2025-10-14OGN9.560.760.3782134
2025-10-15OGN9.550.760.4582246
2025-10-16OGN9.380.760.5382092
2025-10-17OGN9.280.751.9682093
2025-10-20OGN9.240.890.2565994
2025-10-21OGN9.020.8013.1368273
2025-10-22OGN8.931.100.7380781
2025-10-23OGN9.051.090.6381499
2025-10-24OGN9.151.091.1481956
2025-10-27OGN7.051.091.4982476
2025-10-28OGN6.640.981.6389213
2025-10-29OGN6.341.120.6298575
2025-10-30OGN6.571.100.34101732
2025-10-31OGN6.731.090.35102226
2025-11-03OGN6.71.050.45105946
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-10-06OGN10.857.5- 3.85
2025-10-07OGN10.607.5- 3.85
2025-10-08OGN10.257.5- 3.85
2025-10-09OGN9.917.5- 3.85
2025-10-10OGN9.607.5- 3.85
2025-10-13OGN9.607.5- 3.85
2025-10-14OGN9.557.5- 3.85
2025-10-15OGN9.567.5- 3.85
2025-10-16OGN9.377.5- 3.85
2025-10-17OGN9.287.5- 3.85
2025-10-20OGN9.247.0- 3.85
2025-10-21OGN9.027.0- 3.85
2025-10-22OGN8.947.0- 3.85
2025-10-23OGN9.057.0- 3.85
2025-10-24OGN9.157.0- 3.85
2025-10-27OGN7.057.0- 3.85
2025-10-28OGN6.667.0- 3.85
2025-10-29OGN6.347.0- 3.85
2025-10-30OGN6.577.0- 3.85
2025-10-31OGN6.757.0- 3.85
2025-11-03OGN6.707.0- 3.85
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-10-06OGN8.703.305.29
2025-10-07OGN8.703.305.29
2025-10-08OGN8.703.305.29
2025-10-09OGN8.703.305.29
2025-10-10OGN8.703.304.95
2025-10-13OGN8.703.224.95
2025-10-14OGN8.703.224.95
2025-10-15OGN8.703.224.95
2025-10-16OGN8.703.224.95
2025-10-17OGN8.703.224.95
2025-10-20OGN8.703.454.95
2025-10-21OGN8.703.454.95
2025-10-22OGN8.703.454.95
2025-10-23OGN8.703.454.95
2025-10-24OGN8.703.454.95
2025-10-27OGN8.703.424.69
2025-10-28OGN8.703.424.69
2025-10-29OGN8.703.424.69
2025-10-30OGN8.703.424.69
2025-10-31OGN8.703.424.69
2025-11-03OGN8.702.194.69
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

1

Avg. EPS Est. Current Quarter

0.93

Avg. EPS Est. Next Quarter

0.9

Insider Transactions

8.7

Institutional Transactions

2.19

Beta

0.55

Average Sales Estimate Current Quarter

1566

Average Sales Estimate Next Quarter

1607

Fair Value

13.18

Quality Score

77

Growth Score

61

Sentiment Score

13

Actual DrawDown %

83

Max Drawdown 5-Year %

Target Price

10.83

P/E

2.49

Forward P/E

1.66

PEG

6.23

P/S

0.28

P/B

2.38

P/Free Cash Flow

2.65

EPS

2.69

Average EPS Est. Cur. Y​

3.85

EPS Next Y. (Est.)

4.04

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

11.14

Relative Volume

1.26

Return on Equity vs Sector %

69.8

Return on Equity vs Industry %

59.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

Organon & Co.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 10000
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
stock quote shares OGN – Organon & Co. Stock Price stock today
news today OGN – Organon & Co. stock forecast ,stock prediction 2023 2024 2025
marketwatch OGN – Organon & Co. yahoo finance google finance
stock history OGN – Organon & Co. invest stock market
stock prices OGN premarket after hours
ticker OGN fair value insiders trading